Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients

AIDS. 2008 Jul 31;22(12):1513-5. doi: 10.1097/QAD.0b013e3282f7370d.

Abstract

We explored the link between serum alpha-fetoprotein levels and virologic response in 383 HIV-hepatitis C virus coinfected patients. A low alpha-fetoprotein level (<5.0 ng/ml) was an independent predictor of sustained virologic response (odds ratio = 1.83; 95% confidence interval 1.05-3.20). Serum alpha-fetoprotein measurement should be integrated in the pretreatment assessment of prognostic factors of a virologic response.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Biomarkers / blood
  • Drug Therapy, Combination
  • Female
  • HIV Infections / complications*
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Male
  • Polyethylene Glycols
  • Recombinant Proteins
  • Ribavirin / therapeutic use
  • Treatment Outcome
  • alpha-Fetoproteins / metabolism*

Substances

  • Antiviral Agents
  • Biomarkers
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • alpha-Fetoproteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2b